Since 2020, Andreas Mackensen is the director of the Bavarian Center for Cancer Research (BZKF) and currently serves as a member of the KOSMAS Advisory Board.

Prof. Andreas Mackensen received his approbation as physician and MD degree from the University of Freiburg, Germany in 1988. After an internship (Dept. of Internal Medicine I, University of Freiburg), he was a postdoctoral fellow from the German Research Foundation (DFG) between 1991 and 1993 at the Institute Gustave Roussy, Villejuif, France (Prof. Thierry Hercend). His research focus was on the characterization of tumor-specific immune responses in spontaneously regressive melanoma.

Back in Freiburg, he completed his training as a hematologist/oncologist and habilitated in Internal Medicine 1998. From 1999-2007 Andreas Mackensen was Professor (C3) for Hematology/Oncology at the University of Regensburg. He initiated one of the first European Phase I clinical trials with adoptively transferred tumor-reactive T cells in advanced malignant melanoma. In 2007 Andreas Mackensen became full professor for Hematology/Oncology and Director of the Dept. of Internal Medicine 5 – Hematology/Oncology at the University of Erlangen. A. Mackensen is a principal investigator in different investigator-initiated cell-based immunotherapy studies with CAR T-cells for patients with hematologic diseases and solid tumors.